Novo Nordisk A/S

CPSE:NOVO B Stock Report

Market Cap: DKK 2.0t

Novo Nordisk Management

Management criteria checks 3/4

Novo Nordisk's CEO is Lars Jorgensen, appointed in Jan 2017, has a tenure of 8.33 years. directly owns 0.015% of the company’s shares, worth DKK288.59M. The average tenure of the management team and the board of directors is 3.2 years and 7.2 years respectively.

Key information

Lars Jorgensen

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure8.3yrs
CEO ownership0.01%
Management average tenure3.2yrs
Board average tenure7.2yrs

Recent management updates

Recent updates

Why We're Not Concerned About Novo Nordisk A/S' (CPH:NOVO B) Share Price

Apr 24
Why We're Not Concerned About Novo Nordisk A/S' (CPH:NOVO B) Share Price
author-image

EU#2 - From Humble Beginnings to Global Powerhouse

Apr 15CagriSema – a combination therapy for obesity and diabetes that may be even more effective than Wegovy.

We Think Novo Nordisk (CPH:NOVO B) Can Manage Its Debt With Ease

Apr 07
We Think Novo Nordisk (CPH:NOVO B) Can Manage Its Debt With Ease

Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year

Mar 14
Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year

Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year

Feb 28
Novo Nordisk (CPH:NOVO B) Is Paying Out A Larger Dividend Than Last Year
author-image

Novo Nordisk will dominate with GLP-1 products boosting an 8% revenue spike

Feb 13Are there any products or services that could move sales or earnings meaningfully?Most Immediate Catalyst (1–2 Years):Established GLP-1 Products:Ozempic & Rybelsus: driving robust sales and market pe

Novo Nordisk's (CPH:NOVO B) Upcoming Dividend Will Be Larger Than Last Year's

Feb 10
Novo Nordisk's (CPH:NOVO B) Upcoming Dividend Will Be Larger Than Last Year's

The Novo Nordisk A/S (CPH:NOVO B) Full-Year Results Are Out And Analysts Have Published New Forecasts

Feb 07
The Novo Nordisk A/S (CPH:NOVO B) Full-Year Results Are Out And Analysts Have Published New Forecasts

Novo Nordisk A/S (CPH:NOVO B) Not Flying Under The Radar

Jan 09
Novo Nordisk A/S (CPH:NOVO B) Not Flying Under The Radar

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Dec 23
Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)

Nov 13
Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)

Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 09
Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
author-image

Expanding Horizons And Innovation Drive Bold Growth In Pharma's Global Landscape

Nov 07 Strategic market expansion and supply chain investments are set to boost Novo Nordisk's revenue growth through increased production and broader geographical reach.

Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?

Nov 01
Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?

Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable

Oct 09
Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Jul 27
Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?

Jul 05
Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?

A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Jun 09
A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

May 09
Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

CEO Compensation Analysis

How has Lars Jorgensen's remuneration changed compared to Novo Nordisk's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

DKK 101b

Sep 30 2024n/an/a

DKK 95b

Jun 30 2024n/an/a

DKK 90b

Mar 31 2024n/an/a

DKK 89b

Dec 31 2023n/an/a

DKK 84b

Sep 30 2023n/an/a

DKK 75b

Jun 30 2023n/an/a

DKK 67b

Mar 31 2023n/an/a

DKK 61b

Dec 31 2022DKK 60mDKK 17m

DKK 56b

Sep 30 2022n/an/a

DKK 53b

Jun 30 2022n/an/a

DKK 51b

Mar 31 2022n/an/a

DKK 49b

Dec 31 2021DKK 58mDKK 17m

DKK 48b

Sep 30 2021n/an/a

DKK 46b

Jun 30 2021n/an/a

DKK 44b

Mar 31 2021n/an/a

DKK 43b

Dec 31 2020DKK 57mDKK 14m

DKK 42b

Sep 30 2020n/an/a

DKK 42b

Jun 30 2020n/an/a

DKK 41b

Mar 31 2020n/an/a

DKK 40b

Dec 31 2019DKK 55mDKK 14m

DKK 39b

Sep 30 2019n/an/a

DKK 39b

Jun 30 2019n/an/a

DKK 38b

Mar 31 2019n/an/a

DKK 38b

Dec 31 2018DKK 41mDKK 11m

DKK 39b

Compensation vs Market: Insufficient data to establish whether Lars's total compensation is reasonable compared to companies of similar size in the Danish market.

Compensation vs Earnings: Lars's compensation has been consistent with company performance over the past year.

CEO

Lars Jorgensen (58 yo)

8.3yrs

Tenure

DKK 60,100,000

Compensation

Mr. Lars Fruergaard Jorgensen serves as Director at Danmarks Nationalbank since April 2024. He has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member...

Leadership Team

NamePositionTenureCompensationOwnership
Lars Jorgensen
President8.3yrsDKK 60.10m0.015%
DKK 288.6m
Karsten Knudsen
Executive VP7.3yrsDKK 21.50m0.0054%
DKK 105.3m
Henrik Wulff
Executive VP of CMC & Product Supply and Member of the Management Boardno dataDKK 22.00m0.00079%
DKK 15.5m
Martin Lange
Executive VP of Development & Member of the Management Board4.3yrsDKK 20.90mno data
Marcus Schindler
EVP of Research & Early Development4.2yrsDKK 20.90mno data
Maziar Doustdar
Executive VP of International Operations & Member of the Management Boardno datano data0.0019%
DKK 37.6m
Ludovic Helfgott
Executive VP of Product & Portfolio Strategy and Member of Management Boardno datano datano data
Tania Sabroe
EVP of People2.2yrsno datano data
David Moore
Executive VP of US Operations & Member of Management Board2.2yrsno datano data
Thilde Bogebjerg
Executive VP of Qualityless than a yearno datano data
Jacob Martin Rode
Head of Investor Relationsno datano datano data
John Kuckelman
Group General Counsel1.1yrsno datano data

3.2yrs

Average Tenure

54yo

Average Age

Experienced Management: NOVO B's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sylvie Gregoire
Independent Director10.2yrsDKK 1.80m0.00016%
DKK 3.1m
Helge Lund
Independent Chairman of the Board8.2yrsDKK 3.10m0.00014%
DKK 2.7m
Henrik Poulsen
Vice Chairman of the Board4.2yrsDKK 2.00m0.00030%
DKK 5.9m
Laurence Debroux
Independent Director6.2yrsDKK 2.00m0.000010%
DKK 195.8k
Martin MacKay
Independent Director7.2yrsDKK 1.70m0.00015%
DKK 2.9m
Andreas Fibig
Independent Director7.2yrsDKK 1.40m0.000030%
DKK 587.4k
Kasim Kutay
Non-Independent Director8.2yrsDKK 1.20m0.000010%
DKK 195.8k
Christina Law
Independent Director3.2yrsDKK 1.30m0.00014%
DKK 2.7m
Liselotte Hyveled
Employee Representative Director3.2yrsDKK 800.00k0.000060%
DKK 1.2m
Mette Jensen
Employee Non-Independent Representative Director7.2yrsDKK 1.20m0.000070%
DKK 1.4m
Thomas Rantzau
Employee Representative Non-Independent Director7.3yrsDKK 1.00m0.000030%
DKK 587.4k
Elisabeth Christensen
Employee Representative Director3.2yrsDKK 800.00k0.000060%
DKK 1.2m

7.2yrs

Average Tenure

58.5yo

Average Age

Experienced Board: NOVO B's board of directors are considered experienced (7.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/06 05:53
End of Day Share Price 2025/05/06 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novo Nordisk A/S is covered by 71 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Kamla SinghAlphaValue
Gerhard SchwarzBaader Helvea Equity Research